Drug intelligence / Profile preview

CTAP-201

Development stage: Phase 1
Lead developer: OPKO Health
Modality: Small Molecules
Administration: Injectable

Overview

CTAP-201 is an investigational injectable drug developed for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD). It acts as a parathyroid hormone (PTH) reducer, aiming to manage elevated PTH levels commonly seen in CKD and SHPT. The drug has undergone Phase I clinical trials in hemodialysis patients and is part of a portfolio targeting disorders related to altered vitamin D metabolism in CKD. CTAP-201 was originally developed by Cytochroma and later associated with OPKO Health.

Other names: calcifediol injection25-hydroxyvitamin D3 injection25-hydroxycholecalciferol injection

Targets

PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)

Beyond the preview

Go deeper on CTAP-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTAP-201.

Explore the full profile